South Korea · Delayed Price · Currency is KRW ST Pharm Statistics
Total Valuation
ST Pharm has a market cap or net worth of KRW 1.94 trillion. The enterprise value is 1.84 trillion.
| Market Cap | 1.94T |
| Enterprise Value | 1.84T |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
ST Pharm has 20.88 million shares outstanding. The number of shares has increased by 9.11% in one year.
| Current Share Class | 20.88M |
| Shares Outstanding | 20.88M |
| Shares Change (YoY) | +9.11% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 7.35% |
| Owned by Institutions (%) | 14.25% |
| Float | 13.15M |
Valuation Ratios
The trailing PE ratio is 25.44 and the forward PE ratio is 24.02. ST Pharm's PEG ratio is 0.78.
| PE Ratio | 25.44 |
| Forward PE | 24.02 |
| PS Ratio | 5.01 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 3.16 |
| P/FCF Ratio | 25.04 |
| P/OCF Ratio | 17.18 |
| PEG Ratio | 0.78 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.58, with an EV/FCF ratio of 23.80.
| EV / Earnings | 23.95 |
| EV / Sales | 4.76 |
| EV / EBITDA | 17.58 |
| EV / EBIT | 25.97 |
| EV / FCF | 23.80 |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.12.
| Current Ratio | 2.28 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.72 |
| Debt / FCF | 0.97 |
| Interest Coverage | 17.55 |
Financial Efficiency
Return on equity (ROE) is 13.61% and return on invested capital (ROIC) is 12.40%.
| Return on Equity (ROE) | 13.61% |
| Return on Assets (ROA) | 5.60% |
| Return on Invested Capital (ROIC) | 12.40% |
| Return on Capital Employed (ROCE) | 10.87% |
| Weighted Average Cost of Capital (WACC) | 5.92% |
| Revenue Per Employee | 590.01M |
| Profits Per Employee | 117.25M |
| Employee Count | 655 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, ST Pharm has paid 9.22 billion in taxes.
| Income Tax | 9.22B |
| Effective Tax Rate | 10.71% |
Stock Price Statistics
The stock price has increased by +1.97% in the last 52 weeks. The beta is 0.31, so ST Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +1.97% |
| 50-Day Moving Average | 103,886.00 |
| 200-Day Moving Average | 128,789.00 |
| Relative Strength Index (RSI) | 43.09 |
| Average Volume (20 Days) | 130,726 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ST Pharm had revenue of KRW 386.46 billion and earned 76.80 billion in profits. Earnings per share was 3,644.39.
| Revenue | 386.46B |
| Gross Profit | 151.46B |
| Operating Income | 70.82B |
| Pretax Income | 86.06B |
| Net Income | 76.80B |
| EBITDA | 104.62B |
| EBIT | 70.82B |
| Earnings Per Share (EPS) | 3,644.39 |
Balance Sheet
The company has 170.44 billion in cash and 74.81 billion in debt, with a net cash position of 95.63 billion or 4,580.49 per share.
| Cash & Cash Equivalents | 170.44B |
| Total Debt | 74.81B |
| Net Cash | 95.63B |
| Net Cash Per Share | 4,580.49 |
| Equity (Book Value) | 629.07B |
| Book Value Per Share | 30,152.21 |
| Working Capital | 250.90B |
Cash Flow
In the last 12 months, operating cash flow was 112.63 billion and capital expenditures -35.33 billion, giving a free cash flow of 77.29 billion.
| Operating Cash Flow | 112.63B |
| Capital Expenditures | -35.33B |
| Depreciation & Amortization | 33.80B |
| Net Borrowing | -6.25B |
| Free Cash Flow | 77.29B |
| FCF Per Share | 3,702.45 |
Margins
Gross margin is 39.19%, with operating and profit margins of 18.33% and 19.87%.
| Gross Margin | 39.19% |
| Operating Margin | 18.33% |
| Pretax Margin | 22.27% |
| Profit Margin | 19.87% |
| EBITDA Margin | 27.07% |
| EBIT Margin | 18.33% |
| FCF Margin | 20.00% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.54%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.57% |
| Buyback Yield | -9.11% |
| Shareholder Yield | -8.57% |
| Earnings Yield | 3.97% |
| FCF Yield | 3.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for ST Pharm is 177,777.78, which is 91.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 177,777.78 |
| Price Target Difference | 91.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 22.53% |
| EPS Growth Forecast (3Y) | 28.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ST Pharm has an Altman Z-Score of 8.2 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.2 |
| Piotroski F-Score | 7 |